One pitch, two goals: why founders and investors often speak different languages
In life sciences, a pitch has to carry more weight than most.
It has to explain the science, establish credibility, frame the market, clarify the development path, and make the opportunity feel de-risked. But founders often approach that task from different starting points.
Science-led founders tend to begin with the biology, preserving the rigor, nuance, and evidence that underpin years of discovery. Business-led founders may begin with the market, unmet need, and financial upside, building the case around opportunity and scale.
Both instincts make sense. Both can also create gaps. One can bury the opportunity inside the science. The other can make the opportunity sound attractive before the science has earned belief.
Investors enter the room with a different task in mind. They are trying to quickly understand whether the opportunity is clear, differentiated, de-risked enough for its stage, and worth spending more time on.
Both sides may be acting rationally. Yet they often leave the same meeting with different impressions.
Want a quick outside view on whether your pitch is connecting science, risk, and value clearly?
What life sciences founders are trying to say
Life sciences founders are not trying to complicate the story. They are trying to explain why the company matters without losing what makes it credible.
But a thorough explanation does not guarantee clarity. A founder may accurately explain the target biology, mechanism, preclinical package, platform, indication strategy, competitive landscape, clinical rationale, market opportunity, unmet need, and financial upside. Yet without the right structure, the story can still feel either too technical to follow or too commercial to fully believe.
Part of the challenge is human. The deeper someone is in the science, the harder it can be to see where others may lose the thread. The National Academies has noted that even scientists can struggle with quantitative and probabilistic information outside their own area of expertise, which is especially relevant in life sciences, where uncertainty, risk, and data interpretation sit at the center of the story.1 Harvard Business Review has described a related problem as the “curse of knowledge”: when experts are so immersed in the logic of their field that they forget what it sounds like to someone outside it.2
The more technically dense the story becomes, the easier it is for differentiation to disappear inside the explanation. This matters because investor attention is limited. Research indicates that investors tend to spend significantly less time on presentations they reject than on those that advance to diligence.3
In that environment, the story must be compelling while satisfying scientific scrutiny and investment logic.
What investors want to hear
Investors are not entering the conversation with the same mental map as the founders.
They are listening for patterns, priorities, and risks. In a single week, they may see platform companies, asset-centric biotechs, diagnostics, medical devices, and therapeutics, each with its own timeline and risk profile.
So, when a pitch is dense, the investor is not only asking, “Do I understand the science?”
They are asking:
- Why is this opportunity more compelling than the next one?
- Can this opportunity lead to a compelling exit?
- What risk has already been reduced?
- Are the development steps clear?
- Is the next inflection point achievable quickly?
- What is the investable thesis?
Scientific detail or large market projections can help build belief, but only if they are organized to answer investors’ questions. Without that structure, investors have to assemble the thesis themselves, infer what matters most, and work too hard to see the opportunity.
The strongest pitches make the science easier to evaluate. They give investors a clear path through the science, the risk, the value, and the reason to keep paying attention.
The question worth asking
Before the next investor meeting, financing process, or strategic conversation, ask one question:
Is your pitch explaining the science, or is it making the opportunity too clear to pass on?
For many life sciences companies, the gap is not in the data. It is in the story connecting that data to value, differentiation, and belief.
That is where Theoria closes the gap. We work with life sciences companies to turn complex science into a clear, investable narrative that can move across the capital cycle with confidence.
If your science is strong but the story still feels too complex, let’s talk.
[Can’t see the form? contact us here]